Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Assets (2016 - 2025)

Historic Assets for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $189.4 million.

  • Anika Therapeutics' Assets fell 1813.62% to $189.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.4 million, marking a year-over-year decrease of 1813.62%. This contributed to the annual value of $202.7 million for FY2024, which is 2508.65% down from last year.
  • As of Q3 2025, Anika Therapeutics' Assets stood at $189.4 million, which was down 1813.62% from $187.7 million recorded in Q2 2025.
  • Anika Therapeutics' Assets' 5-year high stood at $363.1 million during Q2 2021, with a 5-year trough of $187.7 million in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' median Assets value was $328.9 million (recorded in 2023), while the average stood at $295.5 million.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 45.84% in 2022, then tumbled by 2948.37% in 2024.
  • Over the past 5 years, Anika Therapeutics' Assets (Quarter) stood at $347.5 million in 2021, then grew by 0.46% to $349.1 million in 2022, then decreased by 22.48% to $270.6 million in 2023, then fell by 25.09% to $202.7 million in 2024, then fell by 6.56% to $189.4 million in 2025.
  • Its Assets stands at $189.4 million for Q3 2025, versus $187.7 million for Q2 2025 and $190.6 million for Q1 2025.